Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Recurrence × Paclitaxel × Clear all

Phase

Status

Sponsor Class

OTHER 22 INDUSTRY 18 UNKNOWN 1 OTHER_GOV 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Esophageal Neoplasms 7 Breast Neoplasms 5 Stomach Neoplasms 4 Uterine Cervical Neoplasms 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Thymoma 1 Small Cell Lung Carcinoma 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasm Metastasis 1 Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 EGFR Positive Non-small Cell Lung Cancer 1 Carcinoma, Ovarian Epithelial 1

Interventions

Surgical Procedures, Operative 2 Dexamethasone 2 temoporfin 1 pomalidomide 1 pembrolizumab 1 nimotuzumab 1 liposomal doxorubicin 1 ledipasvir 1 ibrutinib 1 Vinorelbine 1 Tomography, X-Ray Computed 1 Thalidomide 1 Sofosbuvir 1 Rituximab 1 Ribavirin 1 Radiotherapy 1 Radiation 1 Paclitaxel 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Mitoxantrone 1 Mastectomy 1 Irinotecan 1 Immunotherapy, Adoptive 1 Hematologic Tests 1 Drug Therapy 1 Docetaxel 1 Diagnostic Imaging 1 Dermoscopy 1 Cyclophosphamide 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06670911 2025-02-24

ACCESS-I

Instituto Nacional de Cancer, Brazil

Phase 2 Recruiting

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡